A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Healthy Volunteers

Interventions

DRUG

1 x 30 mg/mL pegvisomant

Subcutaneous injection, 30 mg, single dose.

DRUG

2 x 15 mg/mL pegvisomant

Subcutaneous injection, 2 injections of 15 mg, single dose.

Trial Locations (1)

Pfizer Investigational Site, Brussels